These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 21266847)
21. Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine. Theisen M; Jore MM; Sauerwein R Expert Rev Vaccines; 2017 Apr; 16(4):329-336. PubMed ID: 28043178 [TBL] [Abstract][Full Text] [Related]
22. Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display. Singh SK; Thrane S; Janitzek CM; Nielsen MA; Theander TG; Theisen M; Salanti A; Sander AF Vaccine; 2017 Jun; 35(30):3726-3732. PubMed ID: 28578824 [TBL] [Abstract][Full Text] [Related]
23. Prevalence of Plasmodium falciparum transmission reducing immunity among primary school children in a malaria moderate transmission region in Zimbabwe. Paul NH; Vengesai A; Mduluza T; Chipeta J; Midzi N; Bansal GP; Kumar N Acta Trop; 2016 Nov; 163():103-8. PubMed ID: 27491342 [TBL] [Abstract][Full Text] [Related]
24. Functional Characterization and Comparison of Nikolaeva D; Illingworth JJ; Miura K; Alanine DGW; Brian IJ; Li Y; Fyfe AJ; Da DF; Cohuet A; Long CA; Draper SJ; Biswas S Mol Cell Proteomics; 2020 Jan; 19(1):155-166. PubMed ID: 29089373 [No Abstract] [Full Text] [Related]
25. Current developments in malaria transmission-blocking vaccines. Stowers A; Carter R Expert Opin Biol Ther; 2001 Jul; 1(4):619-28. PubMed ID: 11727498 [TBL] [Abstract][Full Text] [Related]
32. Poor CD4 Zaric M; Marini A; Nielsen CM; Gupta G; Mekhaiel D; Pham TP; Elias SC; Taylor IJ; de Graaf H; Payne RO; Li Y; Silk SE; Williams C; Hill AVS; Long CA; Miura K; Biswas S Front Immunol; 2021; 12():732667. PubMed ID: 34659219 [No Abstract] [Full Text] [Related]
33. Immunogenicity and malaria transmission reducing potency of Pfs48/45 and Pfs25 encoded by DNA vaccines administered by intramuscular electroporation. Datta D; Bansal GP; Gerloff DL; Ellefsen B; Hannaman D; Kumar N Vaccine; 2017 Jan; 35(2):264-272. PubMed ID: 27912985 [TBL] [Abstract][Full Text] [Related]
34. Structural and Immunological Characterization of Recombinant 6-Cysteine Domains of the Plasmodium falciparum Sexual Stage Protein Pfs230. MacDonald NJ; Nguyen V; Shimp R; Reiter K; Herrera R; Burkhardt M; Muratova O; Kumar K; Aebig J; Rausch K; Lambert L; Dawson N; Sattabongkot J; Ambroggio X; Duffy PE; Wu Y; Narum DL J Biol Chem; 2016 Sep; 291(38):19913-22. PubMed ID: 27432885 [TBL] [Abstract][Full Text] [Related]
35. Development of a bivalent conjugate vaccine candidate against malaria transmission and typhoid fever. An SJ; Scaria PV; Chen B; Barnafo E; Muratova O; Anderson C; Lambert L; Chae MH; Yang JS; Duffy PE Vaccine; 2018 May; 36(21):2978-2984. PubMed ID: 29681410 [TBL] [Abstract][Full Text] [Related]
36. Transmission-blocking immunity against malaria and other vector-borne diseases. Kaslow DC Curr Opin Immunol; 1993 Aug; 5(4):557-65. PubMed ID: 8216932 [TBL] [Abstract][Full Text] [Related]
37. Functional characterization of Plasmodium berghei PSOP25 during ookinete development and as a malaria transmission-blocking vaccine candidate. Zheng W; Liu F; He Y; Liu Q; Humphreys GB; Tsuboi T; Fan Q; Luo E; Cao Y; Cui L Parasit Vectors; 2017 Jan; 10(1):8. PubMed ID: 28057055 [TBL] [Abstract][Full Text] [Related]
38. Functional comparison of Plasmodium falciparum transmission-blocking vaccine candidates by the standard membrane-feeding assay. Miura K; Takashima E; Deng B; Tullo G; Diouf A; Moretz SE; Nikolaeva D; Diakite M; Fairhurst RM; Fay MP; Long CA; Tsuboi T Infect Immun; 2013 Dec; 81(12):4377-82. PubMed ID: 24042109 [TBL] [Abstract][Full Text] [Related]
39. Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25, a Plasmodium falciparum transmission-blocking vaccine antigen. Coban C; Ishii KJ; Stowers AW; Keister DB; Klinman DM; Kumar N Infect Immun; 2004 Jan; 72(1):584-8. PubMed ID: 14688140 [TBL] [Abstract][Full Text] [Related]
40. Differential ability of specific regions of Plasmodium falciparum sexual-stage antigen, Pfs230, to induce malaria transmission-blocking immunity. Bustamante PJ; Woodruff DC; Oh J; Keister DB; Muratova O; Williamson KC Parasite Immunol; 2000 Aug; 22(8):373-80. PubMed ID: 10972844 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]